IAN SMITH, Royal Marsden Hospital, London
REFERENCE: Lancet 369:29
Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in the Lancet. Ian Smith gave Peter Goodwin three-year follow up results from the Herceptin Adjuvant (HERA) Study conducted among 3,000 women in Europe.
Reporting from:
ECCO-13 The European Cancer Conference, Paris, October 30–November 3, 2005
In this edition:
Martine Piccart gave the Paris ECCO conference her
Dennis Slamon, UCLA School of Medicine, Los Angeles
It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with
Post a comment